GlassScriptPhysician profile
Mandy L Abram
NPI 1447547310
$10,642.64
in general payments reported to CMS, 2019-2025
33 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $4,374 · 2023: $5,179 · 2024: $564 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $3,883 · Food and Beverage: $2,027 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $3,883.30 |
| Food and Beverage | $2,027.03 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $7,468.33 | 2022-2023 | Video Colonoscope, Nds, Endo Stratus Irrigation Pump |
| Abbvie INC. | $476.30 | 2021-2024 | Viberzi, Linzess, Ubrelvy |
| Lilly USA, LLC | $447.93 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $304.77 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $223.31 | 2021-2025 | |
| Novo Nordisk INC | $203.49 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.84 | 2021-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Amgen INC. | $158.47 | 2023-2025 | Otezla, Repatha, Otezla |
| Gilead Sciences, INC. | $143.92 | 2023 | Epclusa |
| Glaxosmithkline, LLC. | $102.65 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $99.85 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $98.78 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $96.11 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $76.86 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $70.94 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $55.30 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $49.27 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $47.49 | 2021-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $45.85 | 2022-2023 | Xarelto |
| Dexcom, INC. | $37.90 | 2023-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $37.58 | 2021 | |
| Shield Therapeutics INC | $34.41 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $23.93 | 2022 | |
| Boston Scientific Corporation | $22.18 | 2025 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $18.43 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $18.27 | 2021 | |
| Abbott Laboratories | $17.62 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.52 | 2022 | |
| Impel Pharmaceuticals INC. | $17.17 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.38 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.09 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $14.54 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Abram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.